Persistence of antibody to 23-valent pneumococcal polysaccharide vaccine: a 5-year prospective follow-up cohort study

Background Pneumococcal vaccines are effective in preventing pneumococcal diseases in adults. The evaluation of the antibodies persistence to the 23-valent pneumococcal polysaccharide vaccine (PPV23) could provide evidence on PPV23 revaccination.Research design and methods Adults aged ≥ 60 years wer...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Expert Review of Vaccines
المؤلفون الرئيسيون:	Xiang Guo, Juan Li, Jing Qiu, Rui Zhang, Jia Ren, Zhuoying Huang, Zhi Li, Xiufang Liang, Fang Lan, Juan Chen, Fang Huang, Xiaodong Sun
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Taylor & Francis Group 2024-12-01
الموضوعات:	23-valent pneumococcal polysaccharide vaccine pneumococcal disease immunogenicity older adults antibody persistence
الوصول للمادة أونلاين:	https://www.tandfonline.com/doi/10.1080/14760584.2023.2296934

مواد مشابهة

Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60–70 years in Shanghai, China
حسب: Jing Qiu, وآخرون
منشور في: (2025-07-01)

Immunogenicity, Safety, and Clinical Eﬀectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine in Patients With Spondyloarthritis (Preliminary Data)
حسب: M. M. Baranova, وآخرون
منشور في: (2022-04-01)

Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly
حسب: Kenji Kawakami, وآخرون
منشور في: (2018-08-01)

Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects
حسب: Salil Bendre, وآخرون
منشور في: (2024-02-01)

Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects
حسب: Salil Bendre, وآخرون
منشور في: (2024-02-01)

A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly
حسب: Lili Huang, وآخرون
منشور في: (2019-01-01)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
حسب: Thundon Ngamprasertchai, وآخرون
منشور في: (2023-06-01)

Safety and Immunogenicity of a 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Chinese Children, Adults and the Elderly: A Phase 4, Randomized, Double-Blind, Active-Controlled Clinical Trial
حسب: Xiaoyu Liu, وآخرون
منشور في: (2025-08-01)

Vaccination pattern of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Hangzhou, China: a coverage and adverse events following immunization of different age groups
حسب: Yan Liu, وآخرون
منشور في: (2021-01-01)

Lot-to-lot consistency, immunogenicity, and safety of a 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy adults aged 40–65 years: A randomized, double-blind, controlled, phase IV clinical trial
حسب: Yunong Zhang, وآخرون
منشور في: (2025-12-01)

Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis
حسب: B. Ts. Batozhargalova, وآخرون
منشور في: (2024-09-01)

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Administered Concomitantly with a 23-Valent Pneumococcal Polysaccharide Vaccine in Adults Aged 60 Years and Older
حسب: Zhongkui Zhu, وآخرون
منشور في: (2024-08-01)

Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up
حسب: Lili Huang, وآخرون
منشور في: (2025-12-01)

Durability of Antibody Response after Primary Pneumococcal Double-Dose Prime-Boost Vaccination in Adult Kidney Transplant Recipients and Candidates: 18-Month Follow-Up in a Non-Blinded, Randomised Clinical Trial
حسب: Lykke Larsen, وآخرون
منشور في: (2022-07-01)

The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases
حسب: Wanqin Tang, وآخرون
منشور في: (2025-08-01)

Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark
حسب: Katrine Finderup Nielsen, وآخرون
منشور في: (2024-06-01)

Correction: The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases
حسب: Frontiers Production Office
منشور في: (2025-08-01)

Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial
حسب: Kei Nakashima, وآخرون
منشور في: (2018-08-01)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
حسب: Germaine Hanquet, وآخرون
منشور في: (2022-01-01)

Effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal disease in children with acute respiratory illness: a hospital- based test-negative design study
حسب: Jiaming SHEN, وآخرون
منشور في: (2023-11-01)

Preventive effects of 23-valent pneumococcal polysaccharide vaccine on community-acquired pneumonia hospitalization in older individuals in China: A case-control study
حسب: Na Liu, وآخرون
منشور في: (2024-12-01)

Vaccination of 23-valent pneumococcal polysaccharide vaccine and its influencing factors in the elderly aged ≥ 65 years: a cross-sectional survey in Changshu city
حسب: Wancheng ZHANG, وآخرون
منشور في: (2024-02-01)

Safety and efficacy of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus
حسب: G. M. Tarasova, وآخرون
منشور في: (2021-06-01)

Impact of the 23-valent pneumococcal polysaccharide vaccination in pregnancy against infant acute lower respiratory infections in the Northern Territory of Australia
حسب: Michael J. Binks, وآخرون
منشور في: (2018-12-01)

INVESTIGATION OF IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
حسب: G. M. Tarasova, وآخرون
منشور في: (2018-09-01)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
حسب: Mikkelsen Malene B, وآخرون
منشور في: (2023-08-01)

Safety of co-vaccination with 23-valent pneumococcal polysaccharide vaccine and split influenza virus vaccine in key populations: an active surveillance study in 8 cities of Anhui province
حسب: Tao LI, وآخرون
منشور في: (2024-07-01)

Vaccine effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: a systematic search and meta-analysis
حسب: Melina Gade Sikjær, وآخرون
منشور في: (2023-01-01)

Immunogenicity, Tolerability, and Clinical Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus
حسب: G. M. Tarasova, وآخرون
منشور في: (2020-08-01)

A narrative review on vaccination rate and factors associated with the willingness to receive pneumococcal vaccine in Chinese adult population
حسب: Bai Yunhua, وآخرون
منشور في: (2022-11-01)

Severe Inflammatory Response in Myelodysplastic Syndrome and Trisomy 8 Following 23-Valent Polysaccharide Pneumococcal Vaccine Administration
حسب: Hirohisa Fujikawa, وآخرون
منشور في: (2021-02-01)

A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older
حسب: Kenji Kawakami, وآخرون
منشور في: (2020-07-01)

Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease
حسب: Nobuharu Ohshima, وآخرون
منشور في: (2020-09-01)

Safety of simultaneous vaccination of 13-valent pneumococcal polysaccharide conjugate vaccine with other vaccines in Shanghai from 2017 to 2021
حسب: YANG Shoufei, وآخرون
منشور في: (2022-08-01)

Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia
حسب: Kenichi Takeshita, وآخرون
منشور في: (2021-10-01)

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease
حسب: Charu Sabharwal, وآخرون
منشور في: (2022-11-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
حسب: N. L. Chernaya, وآخرون
منشور في: (2012-02-01)

A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) revaccination coverage rate among elderly adults aged 65 and older and physician’s attitude
حسب: Atsushi Nakamura, وآخرون
منشور في: (2020-09-01)

23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type <i>Streptococcus pneumoniae</i>
حسب: Thomas Chandler, وآخرون
منشور في: (2022-03-01)

A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants
حسب: Yasunori Ishihara, وآخرون
منشور في: (2024-04-01)